The short version of GHRH analog fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-01-17. Anything still debated is marked as such rather than presented as settled.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
| Property | Value | Notes |
|---|---|---|
| Molecular weight, DAC form | About 3647 Da | Varies with salt form |
| Molecular weight, non-DAC form | About 3358 Da | MOD GRF(1-29) |
| Solubility class | Water soluble | Also dissolves in polar solvents |
| Reported half-life, DAC form | About five to eight days | Values from human studies |
| Common synonyms | CJC-1295; MOD GRF(1-29) | Name depends on variant |
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
The mutation alters the structure and function of skeletal muscles producing one of three forms of myopathy: type 3 nemaline myopathy, congenital myopathy with an excess of thin myofilaments (CM) and congenital myopathy with fibre type disproportion (CMFTD). Mutations have also been found that produce core myopathies. Although their phenotypes are similar, in addition to typical nemaline myopathy some specialists distinguish another type of myopathy called actinic nemaline myopathy. In the former, clumps of actin form instead of the typical rods. It is important to state that a patient can show more than one of these phenotypes in a biopsy. The most common symptoms consist of a typical facial morphology (myopathic facies), muscular weakness, a delay in motor development and respiratory difficulties. The course of the illness, its gravity, and the age at which it appears are all variable and overlapping forms of myopathy are also found. A symptom of nemaline myopathy is that "nemaline rods" appear in differing places in type 1 muscle fibres. These rods are non-pathognomonic structures that have a similar composition to the Z disks found in the sarcomere. The pathogenesis of this myopathy is very varied. Many mutations occur in the region of actin's indentation near to its nucleotide binding sites, while others occur in Domain 2, or in the areas where interaction occurs with associated proteins. This goes some way to explain the great variety of clumps that form in these cases, such as Nemaline or Intranuclear Bodies or Zebra Bodies.
== Clinical comparisons of effectiveness == A 2006 review article in the journal "Lasers in Medical Science" compared intense pulsed light (IPL) and both alexandrite and diode lasers. The review found no statistical difference in effectiveness, but a higher incidence of side effects with diode laser-based treatment. Hair reduction after 6 months was reported as 68.75% for alexandrite lasers, 71.71% for diode lasers, and 66.96% for IPL. Side effects were reported as 9.5% for alexandrite lasers, 28.9% for diode lasers, and 15.3% for IPL. All side effects were found to be temporary and even pigmentation changes returned to normal within 6 months. A 2006 meta-analysis of randomized controlled trials found that alexandrite and diode lasers caused 50% hair reduction for up to 6 months, while there was no evidence of hair reduction from intense pulsed light, neodymium-YAG or ruby lasers.
During this initial stage, when methane is relatively abundant, dense mussel beds also form near the cold seep. Mostly composed of species in the genus Bathymodiolus, these mussels are primarily nourished by symbiotic bacteria that also produce energy from methane, similar to their relatives that form mats. Bathymodiolin mussels often supplement this nutrition source by filter feeding on particulate organic matter known as marine snow. Chemosynthetic bivalves are prominent constituents of the fauna of cold seeps and are represented in that setting by five families: Solemyidae, Lucinidae, Vesicomyidae, Thyasiridae, and Mytilidae. This microbial activity produces calcium carbonate, which is deposited on the seafloor and forms a layer of rock. During a period lasting up to several decades, these rock formations attract siboglinid tubeworms, which settle and grow along with the mussels. Like the mussels, tubeworms rely on chemosynthetic bacteria (in this case, a type that needs hydrogen sulfide instead of methane) for survival. True to any symbiotic relationship, a tubeworm also provides for its bacteria by appropriating hydrogen sulfide from the environment. The sulfide not only comes from the water, but is also mined from the sediment through an extensive "root" system that a tubeworm "bush" establishes in the hard, carbonate substrate. A tubeworm bush can contain hundreds of individual worms, which can grow a meter or more above the sediment. Cold seeps do not last indefinitely.
Sources: en.wikipedia.org
A newspaper of 1847 makes an argument on this subject: "In Scotland, in England, in Holland, in Germany, in Prussia, on the coast of the Baltic, the greater part of the population lives on potatoes during six to seven months of the year. Nowhere is bread made from them. France, which was the last to accept the potato as a food substance, is also the first to use it for a purpose that cannot be profitable. What is the use of going to so much trouble to spoil what is good?" Potato bread remains in family or regional use: thus we note the Correzian farcidure, Norwegian lefse and Rēwena bread.
=== Other endocrine conditions === Endocrine diseases that may lead to ketoacidosis include severe forms of hypothyroidism, thyrotoxicosis and adrenal failure. In all cases, the hormone-sensitive lipase in cells is phosphorylated and over-active, resulting in unrestrained lipolysis. Ketonemia and even ketoacidosis may arise from endocrine (non-diabetic) conditions alone, but the combination of endocrine and diabetic ketoacidosis leads to an especially unfavourable prognosis.
In conjunction with the construction of Einstein's first building, New York City built a 1,349-bed, $37.5 million hospital adjacent to the school, now known as the Jacobi Medical Center. Belkin and New York City Mayor Vincent Impellitteri agreed to permit its use as Einstein's teaching hospital. Jacobi is a member of NYC Health + Hospitals, the largest municipal health system in the United States. It serves as both the regional snakebite center and hyperbaric center for the New York tri-state area.
Sources: en.wikipedia.org
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.
The DAC form carries a maleimide group that binds albumin and extends circulation time. The non-DAC form lacks this group and clears much faster. Both share the same receptor-binding core.
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Activation raises cyclic AMP and promotes growth hormone release. Normal feedback pathways remain part of the response.
No. It is a laboratory-made analog of growth hormone-releasing hormone. The natural hormone is a 44-residue peptide, while the analog is built on a shorter 29-residue fragment.